Ganirelix
- Generic Name
- Ganirelix
- Brand Names
- Fyremadel, Orgalutran, Ganirelix Gedeon Richter
- Drug Type
- Small Molecule
- Chemical Formula
- C80H113ClN18O13
- CAS Number
- 124904-93-4
- Unique Ingredient Identifier
- IX503L9WN0
- Background
Ganirelix is a synthetic decapeptide and a competitive gonadotropin-releasing hormone (GnRH) antagonist. Derived from endogenous GnRH, ganirelix has amino acid substitutions. Ganirelix is indicated for controlled ovarian hyperstimulation in assisted reproduction techniques. The first case of pregnancy achieved after the use of ganirelix in an assisted reprod...
- Indication
Ganirelix is indicated for the inhibition of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation for assisted reproduction techniques (ART).
- Associated Conditions
- -
- Associated Therapies
- Controlled ovarian hyperstimulation therapy
A Study to Investigate the Efficacy and Safety of a Single Injection of Corifollitropin Alfa (Organon 36286) for Ovarian Stimulation Using Daily Recombinant Follicle Stimulating Hormone (FSH) as Reference (P05787)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-06-13
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 1509
- Registration Number
- NCT00696800
Early Follicular Supplementation of Ganirelix in IVF 2004
- First Posted Date
- 2007-04-18
- Last Posted Date
- 2008-06-27
- Lead Sponsor
- The Baruch Padeh Medical Center, Poriya
- Target Recruit Count
- 50
- Registration Number
- NCT00461422
- Locations
- 🇮🇱
The Baruch Padeh medical center, Poriya, Tiberias, Israel
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath